GO
Loading...

Sanofi SA

More

  • April 25- JPMorgan Chase& Co's global chairman of investment banking and veteran deal maker James Elliott will retire in June, according to an internal memo seen by Reuters.

  • April 25- Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease- a progressive neurodegenerative disorder- failed the main goal in a mid-stage trial, sending its shares down about 60 percent before the bell.

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • LONDON, April 23- The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

  • M&A in pharma helps European stocks extend rally Tuesday, 22 Apr 2014 | 4:02 AM ET

    *FTSEurofirst 300 up 0.9 pct, Euro STOXX 50 up 0.7 pct. *AstraZeneca jumps 7.4 pct on M&A talk. The euro zone's blue-chip Euro STOXX 50 index added 0.7 percent, to 3,175.96 points.

  • Why this biotech is rushing in as big pharma exits Wednesday, 16 Apr 2014 | 3:23 PM ET
    Barry Greene, Alnylam Pharmaceuticals

    This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.

  • 5-star stock picker Bill Nygren’s new plays Tuesday, 15 Apr 2014 | 2:24 PM ET

    While stocks aren't as cheap as they were a year ago, Bill Nygren made four new portfolio additions.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • PARIS, April 8- Things are changing in France's business world. But if you think that signals the end of the Gallic sneer at "Anglo-Saxon" ways- the free-market bent of the Americans and British- last week's promotion to economy minister for the interventionist Arnaud Montebourg is a reminder that laissez-faire government remains, in France, a linguistic irony.

  • April 2- Bill Gates, the World Bank and other donors are stepping up efforts to fight neglected tropical diseases in Africa and other low-income regions with a $240 million injection of new funding. The new collaboration includes $50 million from the Bill& Melinda Gates Foundation and $50 million from the Children's Investment Fund Foundation.

  • *Up to 100 mln pounds for new drug manufacturing in Africa. *GSK looks at Rwanda, Ghana and Ethiopia for new factories. France's Sanofi has also highlighted Africa as a promising market.

  • *Up to 100 mln pounds for new drug manufacturing in Africa. *GSK looks at Rwanda, Ghana and Ethiopia for new factories. France's Sanofi has also highlighted Africa as a promising growth market.

  • *Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.

  • European stock markets trimmed last week's gains to close lower on Monday, off the back of weak Chinese data and tensions in Ukraine.

  • European shares dip early as China data weighs Monday, 24 Mar 2014 | 5:22 AM ET

    *China's lower-than-expected PMI weighs on sentiment. PARIS, March 24- European stocks slipped in early trade on Monday, trimming last week's lofty gains, as data showing China's manufacturing activity contracted in the first quarter of 2014 revived worries over the outlook for global growth.

  • COPENHAGEN, March 20- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • Wider market sentiment was still undermined by the crisis in Ukraine, where confrontation between Kiev and Moscow showed no sign of easing. The DAX had fallen 2.9 percent in the previous two sessions, dragged down by worries about Ukraine and by disappointing Chinese trade data.